Personnel Information

写真a

INAZAWA Johji


Job title

Professor

Laboratory Address

Department of Molecular Cytogenetics Medical Research Institute, Tokyo Medical and Dental University 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan

Laboratory Phone number

+81-3-5803-5820

Laboratory Fax number

+81-3-5803-0244

Mail Address

The inquiry by e-mail is 《here

Research Areas, Keywords

Medical Genetics, Human Genome, Cancer Genetics, Molecular Cytogenetics, CGH FISH, Oncogene, Tumor Supressor Gene, Cancer Buology, Genetic Diagnosis, Chromosome Aberrations

Graduating School 【 display / non-display

  • Kyoto Prefectural University of Medicine, 1982.03, Graduated

Campus Career 【 display / non-display

  • 1998.04
    -
    Now
    Tokyo Medical and Dental University, Medical Research Institute, Medical Genomics, Molecular Cytogenetics, Professor
  • 1998.04
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Molecular Cytogenetics, Professor
  • 2010.04
    -
    2015.03
    Tokyo Medical and Dental University, Hard Tissue Genome Research Center, Director
  • 2012.05
    -
    2014.03
    Tokyo Medical and Dental University, Joint Institutes for Education and Research, Bioresource Research Center, Director
  • 2014.04
    -
    Now
    Tokyo Medical and Dental University, Research and Industry-University Alliance Organization, Bioresource Research Center, Director

External Career 【 display / non-display

  • Education,
  • 1982 M.D., Kyoto Prefectural University of Medicine,
  • 1991 Ph.D., Kyoto Prefectural University of Medicine,
  • Professional Training and Employment,
  • 2006: Project Leader, Development of Industrial Technology for Human Chromosome Analysis. New Energy and Industrial Technology Developmental Organization (NEDO) Japan,

display all >>

Academic Activity 【 display / non-display

  • Awards and Special Research Funds:
  • 1. Young Investigator's Award of the Japanese Society of Hematology, 1991
  • 2. Young Investigator's Award of Kyoto Prefectural University of Medicine, 1993
  • 3. JCA-Mauvernay Award, from Japan Cancer Association (2006)
  • 4. Honorary Diploma, The Bulgarian National Academy of Medicine Elected, 2006

display all >>

Qualification Acquired 【 display / non-display

  • Doctor

 

Published Papers & Misc 【 display / non-display

  • Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S, Kochi Y, Horikoshi M, Suzuki K, Ito K, Koyama S, Ozaki K, Niida S, Sakata Y, Sakata Y, Kohno T, Shiraishi K, Momozawa Y, Hirata M, Matsuda K, Ikeda M, Iwata N, Ikegawa S, Kou I, Tanaka T, Nakagawa H, Suzuki A, Hirota T, Tamari M, Chayama K, Miki D, Mori M, Nagayama S, Daigo Y, Miki Y, Katagiri T, Ogawa O, Obara W, Ito H, Yoshida T, Imoto I, Takahashi T, Tanikawa C, Suzuki T, Sinozaki N, Minami S, Yamaguchi H, Asai S, Takahashi Y, Yamaji K, Takahashi K, Fujioka T, Takata R, Yanai H, Masumoto A, Koretsune Y, Kutsumi H, Higashiyama M, Murayama S, Minegishi N, Suzuki K, Tanno K, Shimizu A, Yamaji T, Iwasaki M, Sawada N, Uemura H, Tanaka K, Naito M, Sasaki M, Wakai K, Tsugane S, Yamamoto M, Yamamoto K, Murakami Y, Nakamura Y, Raychaudhuri S, Inazawa J, Yamauchi T, Kadowaki T, Kubo M, Kamatani Y. Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. Nature genetics. 2020.07; 52 (7): 669-679. ( PubMed, DOI )

  • Takagawa Y, Gen Y, Muramatsu T, Tanimoto K, Inoue J, Harada H, Inazawa J. miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway. Molecular therapy : the journal of the American Society of Gene Therapy. 2020.06; 28 (6): 1494-1505. ( PubMed, DOI )

  • Gokita K, Inoue J, Ishihara H, Kojima K, Inazawa J. Therapeutic Potential of LNP-Mediated Delivery of miR-634 for Cancer Therapy. Molecular therapy. Nucleic acids. 2020.03; 19 330-338. ( PubMed, DOI )

  • Matsukawa T, Yamamoto T, Honda A, Toya T, Ishiura H, Mitsui J, Tanaka M, Hao A, Shinohara A, Ogura M, Kataoka K, Seo S, Kumano K, Hosoi M, Narukawa K, Yasunaga M, Maki H, Ichikawa M, Nannya Y, Imai Y, Takahashi T, Takahashi Y, Nagasako Y, Yasaka K, Mano KK, Matsukawa MK, Miyagawa T, Hamada M, Sakuishi K, Hayashi T, Iwata A, Terao Y, Shimizu J, Goto J, Mori H, Kunimatsu A, Aoki S, Hayashi S, Nakamura F, Arai S, Momma K, Ogata K, Yoshida T, Abe O, Inazawa J, Toda T, Kurokawa M, Tsuji S. Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy. Brain communications. 2020; 2 (1): fcz048. ( PubMed, DOI )

  • Tanimoto K, Muramatsu T, Inazawa J. Massive computational identification of somatic variants in exonic splicing enhancers using The Cancer Genome Atlas. Cancer medicine. 2019.12; 8 (17): 7372-7384. ( PubMed, DOI )

display all >>

Conference Activities & Talks 【 display / non-display

  • 劉 暢, 玄 泰行, 稲澤 譲治. miR-3140はBRD4-MYCN経路を標的とし、神経芽腫細胞の増殖を抑制する(miR-3140 suppressed tumor cell growth in neuroblastoma by targeting BRD4-MYCN pathway). 日本癌学会総会記事 2019.09.01

  • 吉松 康裕, 赤津 裕一, 高橋 直也, 紀室 志織, 村松 智輝, 桂 彰宏, 間石 奈湖, 鈴木 洋, 稲澤 譲治, 樋田 京子, 宮園 浩平, 渡部 徹郎. 線維芽細胞増殖因子(FGF2)は腫瘍血管内皮細胞においてTGF-βによって誘導される内皮-筋線維芽移行を制御する(Fibroblast growth factor 2 regulates TGF-β-induced endothelial-to-myofibroblast transition of tumor endothelial cells). 日本癌学会総会記事 2019.09.01

  • 内藤 諒, 村松 智輝, 谷本 幸介, 稲澤 譲治. 統合的mRNA, miRNA発現情報を基盤とした独自のマイクロRNA標的遺伝子予測データベースの構築(Construction of an in-house microRNA-target prediction database based on an integrative mRNA-microRNA expression data). 日本癌学会総会記事 2019.09.01

  • 井上 純, 岸川 正大, 濱本 英利, 小林 勝則, 藤原 恭子, 稲澤 譲治. 皮膚扁平上皮癌におけるmiR-634軟膏による抗腫瘍効果(Therapeutic potential of the topical treatment of miR-634 ointment for cutaneous squamous cell carcinoma). 日本癌学会総会記事 2019.09.01

  • 岸川 正大, 井上 純, 濱本 英利, 小林 勝則, 朝蔭 孝宏, 稲澤 譲治. 甲状腺未分化癌に対するmiR-634を用いた核酸抗癌剤の開発(Development of miRNA-formulation using miR-634 for anaplastic thyroid cancer therapy). 日本癌学会総会記事 2019.09.01

display all >>

Patents 【 display / non-display

  • METHOD FOR ASSAYING MICRORNA, CANCER THERAPEUTIC AGENT, AND MEDICINAL COMPOSITION CONTAINING SAME FOR CANCER THERAPY

    Patent Number: 9994843

  • THERAPEUTIC AGENT FOR TREATING A CANCER IN WHICH NRF2 IS STABILIZED

    Patent Number: 2963125